Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -410.84% is 81% above its 1-year average of -2135.50%, near the high end of its 1-year range (-5577.76%–-87.24%).
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -741.51%.
EBITDA MARGIN
-410.84%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Atrium Therapeutics, Inc.
Market Cap
$136.67M
EBITDA Margin
-410.84%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$136.57M
EBITDA Margin
-27.14%
TTM Avg
-20.66%
3Y Avg
-62.77%
5Y Avg
-50.13%
Market Cap
$137.80M
EBITDA Margin
-5.26%
TTM Avg
-11.06%
3Y Avg
-22.91%
5Y Avg
-20.50%
Market Cap
$139.04M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
Market Cap
$139.47M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
Market Cap
$139.84M
EBITDA Margin
-95.26%
TTM Avg
-233.98%
3Y Avg
-174.91%
5Y Avg
-167.88%
Market Cap
$131.21M
EBITDA Margin
5.24%
TTM Avg
5.41%
3Y Avg
5.74%
5Y Avg
10.79%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | $136.67M | -410.84% | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.57M | -27.14% | -20.66% | -62.77% | -50.13% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | -5.26% | -11.06% | -22.91% | -20.50% |
| Immuneering Corporation (IMRX)vs › | $139.04M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -221.15% | -221.15% | -221.15% | -221.15% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -95.26% | -233.98% | -174.91% | -167.88% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $132.03M | -0.19% | -1.66% | -11.02% | -42.72% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | 5.24% | 5.41% | 5.74% | 10.79% |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | 4.63% | -2.31% | -16.32% | -24.77% |
Gross Margin
97.9%
EBITDA Margin
-410.8%
Operating Margin
-410.2%
Net Margin
-396.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -741.51% |
| 2026-03-31 | -87.24% |
| 2025-12-31 | -5577.76% |
